NCT07304713Completed
Probiotic Intervention for People With Multiple Sclerosis
Feasibility and Acceptability of a 12-week Probiotic Intervention to Improve Health Outcomes for People With Multiple Sclerosis: A Single-arm Trial
Source: ClinicalTrials.gov · Last updated 26 Dec 2025
Brief summary (registry, in English)
The goal of this single-arm, mixed methods trial is to learn if it is feasible and acceptable to take a probiotic for 12-weeks in people with Multiple Sclerosis. The main question\[s\] it aims to answer \[is/are\]: * Is it feasible and acceptable for people with MS to take a probiotic for 12-weeks? * Explore impact on health outcomes? Participants will. * Drink 70ml probiotic drink daily as prescribed for 12-weeks. * All data collection will be done remotely. * Before and after 12-weeks participants will complete an online questionnaire (Acceptability, lifestyle behaviour, symptoms, quality of life). * Provide a stool sample to analyse microbiome changes. * Take a short online cognitive test. * Participate in a focus group.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 29 (actual)
- First submitted
- 28 Nov 2025
- Start date
- 20 Jun 2023
- Primary completion date
- 24 Nov 2023
- Lead sponsor
- Sheffield Hallam University
- Diseases
- Multiple sclerosis
- NCT number
- NCT07304713
What you commit to
- Study type: Interventional
- Participants enrolled: 29
- From 20 Jun 2023 to the primary completion date, 24 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Symptom relapse or hospital admission in the prior four weeks.
- Immunocompromised and requiring steroids (not including PwMS taking anti-CD20 monoclonal antibodies \[Ocrevus or Kesimpta\]).
- Antibiotic use in the prior three months.
- Pro-biotic use in the prior four weeks.
- Use of food supplements which target gut health in the prior four weeks.
Other illness
- Type 2 diabetes, Cardiovascular disease, kidney disease, chronic gastrointestinal tract health issues.
Other
- Rapidly progressing MS defined as two of more disabling relapses in the last year.
- Pregnant or lactating.
- Dysphagia.
- Medically advised not to use a probiotic.
Who the study is looking for
- Adults aged 18 years or over.
- Living in the United Kingdom.
- Self-reported clinical diagnosis of MS.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sheffield Hallam University Coordinator of this site? Confirm its status | Sheffield | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.